Century Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| CNTY-813 IND Submission Target | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly217MTarget: Sufficient to support operations into the first quarter of 2029
Quarterly Net Cash Used in Operating Activities Quarterly25.3MTarget: Maintain disciplined capital allocation and tight cost controls
Watch Items
- CNTY-813 IND SubmissionTrigger: Submission of Investigational New Drug (IND) application to the FDAAction: Targeted for Q4 2026; failure to submit on time requires reassessment of the clinical timeline and program prioritization.
- CNTY-308 Clinical InitiationTrigger: Initiation of Phase 1 clinical testing for CD19-targeted CAR-iT cell therapyAction: Targeted for 2026; monitor regulatory clearance and site activation progress.
- CNTY-101 Phase 1/2 CARAMEL Trial ProgressTrigger: Patient enrollment and safety/efficacy readouts in investigator-sponsored trialAction: Review clinical data updates to validate the Allo-Evasion platform's persistence and safety profile.
Research as of 19 Jun 2026